These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31498280)

  • 1. Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel disease.
    Gröchenig HP; Waldhör T; Haas T; Wenzl H; Steiner P; Koch R; Feichtenschlager T; Eckhardt G; Mayer A; Kirchgatterer A; Ludwiczek O; Platzer R; Papay P; Gartner J; Fuchssteiner H; Miehsler W; Peters PG; Reicht G; Kutschera M; Dejaco C; Vogelsang H; Novacek G;
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1211-1219. PubMed ID: 31498280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile.
    Fernández A; Simian D; Quera R; Flores L; Ibáñez P; Lubascher J; Figueroa C; Kronberg U; Pizarro G; Fluxá D
    Complement Ther Med; 2018 Oct; 40():77-82. PubMed ID: 30219473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of complementary and alternative medicine use for patients with inflammatory bowel disease in Korea.
    Park DI; Cha JM; Kim HS; Park HJ; Shin JE; Hong SN; Hong SS; Kim WJ
    Complement Ther Med; 2014 Feb; 22(1):87-93. PubMed ID: 24559822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic delay in patients with inflammatory bowel disease in Austria.
    Novacek G; Gröchenig HP; Haas T; Wenzl H; Steiner P; Koch R; Feichtenschlager T; Eckhardt G; Mayer A; Kirchgatterer A; Ludwiczek O; Platzer R; Papay P; Gartner J; Fuchssteiner H; Miehsler W; Peters PG; Reicht G; Vogelsang H; Dejaco C; Waldhör T;
    Wien Klin Wochenschr; 2019 Mar; 131(5-6):104-112. PubMed ID: 30715607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey.
    Langhorst J; Anthonisen IB; Steder-Neukamm U; Lüdtke R; Spahn G; Michalsen A; Dobos GJ
    Inflamm Bowel Dis; 2005 Mar; 11(3):287-95. PubMed ID: 15735435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease.
    Weizman AV; Ahn E; Thanabalan R; Leung W; Croitoru K; Silverberg MS; Steinhart AH; Nguyen GC
    Aliment Pharmacol Ther; 2012 Feb; 35(3):342-9. PubMed ID: 22176478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease.
    Joos S; Rosemann T; Szecsenyi J; Hahn EG; Willich SN; Brinkhaus B
    BMC Complement Altern Med; 2006 May; 6():19. PubMed ID: 16716218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease.
    Kutschera M; Waldhör T; Gröchenig HP; Haas T; Wenzl H; Steiner P; Koch R; Feichtenschlager T; Eckhardt G; Mayer A; Kirchgatterer A; Ludwiczek O; Platzer R; Papay P; Gartner J; Fuchssteiner H; Peters PG; Reicht G; Moser G; Dejaco C; Vogelsang H; Primas C; Novacek G; Miehsler W;
    United European Gastroenterol J; 2021 Feb; 9(1):72-81. PubMed ID: 32723070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.
    Lakatos PL; Czegledi Z; David G; Kispal Z; Kiss LS; Palatka K; Kristof T; Nagy F; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovacs A; Racz I; Lakatos L
    J Crohns Colitis; 2010 Sep; 4(3):283-90. PubMed ID: 21122517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis.
    Nousiainen P; Merras-Salmio L; Aalto K; Kolho KL
    BMC Complement Altern Med; 2014 Apr; 14():124. PubMed ID: 24708564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
    Lakatos L; Czeglédi Z; Dávid G; Kispál Z; Kiss LS; Palatka K; Kristóf T; Molnár T; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovács A; Rácz I; Lakatos PL
    Orv Hetil; 2010 Feb; 151(7):250-8. PubMed ID: 20133244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary and Alternative Medicine Use in Children With Inflammatory Bowel Disease.
    Phatak UP; Alper A; Pashankar DS
    J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):157-160. PubMed ID: 30499887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey.
    Li FX; Verhoef MJ; Best A; Otley A; Hilsden RJ
    Can J Gastroenterol; 2005 Sep; 19(9):567-73. PubMed ID: 16151549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study.
    Koning M; Ailabouni R; Gearry RB; Frampton CM; Barclay ML
    Inflamm Bowel Dis; 2013; 19(4):767-78. PubMed ID: 23429459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey.
    Bensoussan M; Jovenin N; Garcia B; Vandromme L; Jolly D; Bouché O; Thiéfin G; Cadiot G
    Gastroenterol Clin Biol; 2006 Jan; 30(1):14-23. PubMed ID: 16514377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products.
    Rawsthorne P; Clara I; Graff LA; Bernstein KI; Carr R; Walker JR; Ediger J; Rogala L; Miller N; Bernstein CN
    Gut; 2012 Apr; 61(4):521-7. PubMed ID: 21836028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey.
    Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
    Am J Gastroenterol; 2003 Jul; 98(7):1563-8. PubMed ID: 12873578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Henriques DP; Oliveira RR; Vanni J; Lima HP; Otiti JV; Neves FRM; Hammerle MB; Sassaki LY; Zaltman C
    Arq Gastroenterol; 2022; 59(3):375-382. PubMed ID: 36102435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes.
    Nene S; Gonczi L; Kurti Z; Morin I; Chavez K; Verdon C; Reinglas J; Kohen R; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
    World J Gastroenterol; 2020 Feb; 26(7):759-769. PubMed ID: 32116423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary and alternative medicine (CAM) practices and dietary patterns in children with inflammatory bowel disease in Singapore and Malaysia.
    Ong F; Seah Lee W; Lin C; Ng RT; Yee Wong S; Lim SL; Quak SH; Aw M
    Pediatr Neonatol; 2018 Oct; 59(5):494-500. PubMed ID: 29352665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.